Breaking News

Japan Central Bank Unexpectedly Targets Bigger Expansion of Monetary Base; Yen Drops
Tweet TWEET

Dr. Reddy’s Announces the Launch of Amlodipine Besylate and Atorvastatin Calcium Tablets

  Dr. Reddy’s Announces the Launch of Amlodipine Besylate and Atorvastatin
  Calcium Tablets

Business Wire

HYDERABAD, India -- March 27, 2014

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched
Amlodipine Besylate and Atorvastatin Calcium Tablets 2.5/10mg, 2.5/20mg,
2.5/40mg, 5/10mg, 5/20mg, 5/40mg, 5/80mg, 10/10mg, 10/20mg, 10/40mg and 10/80
mg  a therapeutic equivalent generic version of CADUET^® (amlodipine Besylate
and atorvastatin calcium) tablets, in the US market on March 26, 2014,
following the approval by the United States Food & Drug Administration
(USFDA).

The CADUET^® tablets brand and generic had U.S. sales of approximately $163
Million MAT for the most recent twelve months ending in January 2014 according
to IMS Health*.

Dr. Reddy’s Amlodipine Besylate and Atorvastatin Calcium Tablets are available
in bottle counts of 30 and 90**.

Disclaimer

This press release includes forward-looking statements, as defined in the U.S.
Private Securities Litigation Reform Act of 1995. We have based these
forward-looking statements on our current expectations and projections about
future events. Such statements involve known and unknown risks, uncertainties
and other factors that may cause actual results to differ materially. Such
factors include, but are not limited to, changes in local and global economic
conditions, our ability to successfully implement our strategy, the market
acceptance of and demand for our products, our growth and expansion,
technological change and our exposure to market risks. By their nature, these
expectations and projections are only estimates and could be materially
different from actual results in the future.

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global
pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses - Pharmaceutical
Services and Active Ingredients, Global Generics and Proprietary Products –
Dr. Reddy’s offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated
formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular,
diabetology, oncology, pain management and anti-infective. Major markets
include India, USA, Russia-CIS and Europe apart from other select geographies
within Emerging Markets.  For more information, log on to: www.drreddys.com.

CADUET^® is a registered trademark of Pfizer Inc.

*IMS National Sales Perspectives: Retail and Non-Retail MAT January 2014
**available for select strengths only

Contact:

Dr. Reddy’s Laboratories
Media:
SVS Chowdary, +91-40- 49002448
chowdaryl@drreddys.com
or
Investors and Financial Analysts:
Kedar Upadhye, +91-40-66834297
kedaru@drreddys.com
or
Saunak Savla, +91-40-49002135
saunaks@drreddys.com
or
Milan Kalawadia (USA), 609-375-9831
mkalawadia@drreddys.com
 
Press spacebar to pause and continue. Press esc to stop.